



Docket No. 42982-C1-C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: S. Goldin et al.

SERIAL NO.: 09/637,774

EXAMINER: P. O'Sullivan

FILED: August 11, 2000

GROUP: 1621

FOR: THERAPEUTIC GUANIDINES

ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Sir:

**RESPONSE TO RESTRICTION REQUIREMENT**

Applicants are in receipt of the Office Action dated September 28, 2001 of the above-identified application.

Applicants respectfully reconsideration of the Restriction Requirement. In particular, it is believed that multiple groups could be searched and examined together without undue burden. For instance, searches for multiple groups should be overlapping should be overlapping.

In any event, to provide a complete response to the Restriction, Applicants elect Group III, directed to claims 16, 19, and 21-23.

As a species, Applicants elect N-(4-sec-butylphenyl)-N-(4-tert-butylbenzyl)guanidine, which is recited in claim 4.

Early consideration and allowance of the application are earnestly solicited.

01/09/2002 FMRCER 00000001 041105 09637774

01 FC:215 55.00 CH

#2  
1/4/02  
meun  
RECEIVED  
JAN 03 2001  
TECH CENTER 1600/2900  
RECEIVED  
DEC 31 2001  
TECH CENTER 1600/2900

S. Goldin et al.  
U.S.S.N. 09/637,774  
Page 2

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Peter F. Corless', is written over a horizontal line.

Peter F. Corless (Reg. 33,860)  
Dike, Bronstein, Roberts & Cushman  
Intellectual Property Practice  
Edwards & Angell, LLP  
P.O. Box 9169  
Boston, MA 02209  
Tel: 617-517-5557  
Fax: 617-439-4170